The role of PD-L1 in the radiation response and clinical outcome for bladder cancer

Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges

(2015) Feifei Teng et al.   CANCER LETTERS

Building immunity to cancer with radiation therapy

(2015) Suresh J. Haikerwal et al.   CANCER LETTERS

Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells

(2015) Hyangsoon Noh et al.   Cell Communication and Signaling

Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer

(2015) Yawen Zheng et al.   CELLULAR IMMUNOLOGY

1 ,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling

(2015) P.-T. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma

(2015) Patcharee Ritprajak et al.   ORAL ONCOLOGY

Combination of Radiotherapy and Immune Checkpoint Inhibitors

(2015) Karsten A. Pilones et al.   SEMINARS IN RADIATION ONCOLOGY

DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer

(2015) Chun-Te Wu et al.   Oncotarget

Immunity in Head and Neck Cancer

(2015) J. D. Schoenfeld   Cancer Immunology Research

PD-L1 and Survival in Solid Tumors: A Meta-Analysis

(2015) Pin Wu et al.   PLoS One

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

(2014) A. B. Sharabi et al.   Cancer Immunology Research

Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression

(2014) liufu deng et al.   OncoImmunology

Combinations of Immunotherapy and Radiation in Cancer Therapy

(2014) Ralph E. Vatner et al.   Frontiers in Oncology

Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer

(2013) Christian J. Maine et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CTLA-4 Blockade Enhances Antitumor Immunity of Intratumoral Injection of Immature Dendritic Cells into Irradiated Tumor in a Mouse Colon Cancer Model

(2013) Cheol-Hun Son et al.   JOURNAL OF IMMUNOTHERAPY

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

(2013) Silvia C. Formenti et al.   JNCI-Journal of the National Cancer Institute

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model

(2010) Cheng-Huang Shen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

(2009) Y. Lee et al.   BLOOD

Bladder Preservation in Selected Patients with Muscle-Invasive Bladder Cancer by Complete Transurethral Resection of the Bladder Plus Systemic Chemotherapy: Long-Term Follow-up of a Phase 2 Nonrandomized Comparative Trial with Radical Cystectomy

(2008) Eduardo Solsona et al.   EUROPEAN UROLOGY

Phase I-II RTOG Study (99-06) of Patients With Muscle-Invasive Bladder Cancer Undergoing Transurethral Surgery, Paclitaxel, Cisplatin, and Twice-daily Radiotherapy Followed by Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy

(2008) Donald S. Kaufman et al.   UROLOGY